Spectral Medical Inc. Appoints John E. Nosenzo to its Board of Directors
- Adds significant experience and strength to the Company’s commercialization focus
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
TORONTO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic
options for sepsis and septic shock, announced today that it has appointed John E. Nosenzo as an independent director, effective immediately.
Mr. Nosenzo is currently the Chief Commercial Officer of Bioventus, a global leader in Orthobiologic solutions, and he brings to Spectral more than 25 years of extensive experience within
multi-billion-dollar organizations in Healthcare Sales, Marketing, Service, Operations and General Management including Laboratory Diagnostic, Imaging Modalities, Brand and Generic Pharmaceuticals.
He earned an MBA in marketing and management from Adelphi University and a Bachelor of Science in pharmacy from St. John’s University.
“We are very pleased that John has joined our board at this pivotal time in our Company’s development. His experience in the medical device sector in the U.S. will help guide Spectral’s commercial
activities for our diagnostic and therapeutic approach to septic shock as well as Dialco’s commercialization in the area of renal replacement therapy,” said Dr Paul Walker, President and CEO of
Spectral. The appointment of Mr. Nosenzo fills the vacancy arising from the retirement of Mr. Guillermo Herrera, who joined the Company as a director in 2006.
“On behalf of the board and management team, I would like to thank Guillermo for his commitment and contributions to Spectral during his tenure as director and wish him well in his future
endeavors,” commented Mr. Tony Bihl, Chairman of Spectral’s Board of Directors.
About Spectral
Spectral is a Phase III company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin (“PMX”). PMX is a therapeutic hemoperfusion device that
removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s Endotoxin Activity Assay (EAA), the only FDA cleared diagnostic for the risk of developing sepsis.
PMX has been approved for therapeutic use in Japan and Europe, and has been used safely and effectively on more than 200,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. Approximately 330,000 patients are diagnosed with severe sepsis and septic shock in North America each year.